cancer panel
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
Exact Sciences Q4 Revenues up 58 Percent; Company to Acquire Ashion Analytics From TGen
Exact's planned acquisition of Ashion, a sequencing lab based in Arizona, builds on the company's licensing of the TARDIS liquid biopsy technology from TGen in January.
The study, presented at the NSGC annual conference last week, supports the broader use of panel testing for cancer patients suspected of hereditary disease.Â
Ovarian Cancer Mutational Signatures, Immune Features Tied to Combination Treatment Response
Researchers found tumor and microenvironment features of advanced ovarian cancers respond to combination PARP inhibitor and immune checkpoint treatment.
Thermo Fisher, Janssen Biotech to Develop CDx for Lung Cancer, Other Indications
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.